A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)



Status:Completed
Conditions:Colorectal Cancer, Colorectal Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/23/2019
Start Date:July 5, 2016
End Date:December 26, 2018

Use our guide to learn which trials are right for you!

A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma

This is a Phase III, multicenter, open-label, three-arm, randomized study in participants
with unresectable locally advanced or metastatic colorectal cancer (CRC) who have received at
least two prior regimens of cytotoxic chemotherapy for metastatic disease. The study compares
regorafenib, a standard of care therapy in this setting, to cobimetinib plus atezolizumab and
atezolizumab monotherapy.


Inclusion Criteria:

Disease-specific inclusion criteria:

- Histologically confirmed adenocarcinoma originating from the colon or rectum (Stage 4
American Joint Committee on Cancer [AJCC] 7th edition)

- Experienced disease progression or was intolerant to at least two systemic
chemotherapy regimens for metastatic colorectal cancer that must have included
fluroropyrimidines, irinotecan, and oxaliplatin; adjuvant regimen can be considered as
one chemotherapy regimen for metastatic disease if the participant had disease
recurrence within 6 months of completion; disease progression must have occurred
within 3 months of the last systemic therapy administration

General inclusion criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Anticipated life expectancy greater than or equal to (>=) 3 months

- Adequate hematologic and end organ function

- Women of childbearing potential must agree to appropriately use an effective form of
contraception (failure rate of less than [<] 1 percent [%] per year) during the
treatment period, within 5 months after the last dose of atezolizumab, and within 3
months after the last dose of cobimetinib and regorafenib

- Men must agree not to donate sperm or have intercourse with a female partner without
using appropriate barrier contraception during the treatment period and for 3 months
after the last dose of either cobimetinib or regorafenib

- Provide an archival or newly obtained tumor tissue sample

Exclusion Criteria:

- After the approximate 5% cap for microsatellite (MSI)-high participants is reached,
only MSI-stable participants will be eligible

- Once the 50% cap for wild-type RAS has been reached, only extended RAS-mutant
participants will be eligible

- Major surgery or radiotherapy within 21 days prior to Cycle 1 Day 1 or anticipation of
needing such procedure while receiving study treatment

- Treatment with any anti-cancer agent within 14 days prior to Cycle 1 Day 1

- Uncontrolled tumor-related pain. Participants requiring narcotic pain medication must
be on a stable regimen at study entry

- Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated
drainage more than once every 28 days. Indwelling drainage catheters (e.g., PleurX®)
are allowed

- Active or untreated central nervous system (CNS) metastases are excluded

- Prior therapy with any cancer immunotherapy, MEK inhibitor, or regorafenib

- Participants with active malignancy (other than CRC) or a prior malignancy within the
past 3 years are excluded. Participants with completely resected cutaneous melanoma
(early stage), basal cell carcinoma, cutaneous squamous cell carcinoma, cervical
carcinoma in-situ, breast carcinoma in-situ, and localized prostate cancer are
eligible

- Unstable angina, new onset angina within last 3 months, myocardial infarction within
last 6 months and current congestive heart failure New York Heart Association Class II
or higher

- Left ventricular ejection fraction (LVEF) below institutional lower limit of normal or
below 50%, whichever is lower

- Poorly controlled hypertension, defined as a blood pressure consistently above 150/90
millimeters of Mercury (mmHg) despite optimal medical management

- Human immunodeficiency virus (HIV) infection

- Active tuberculosis infection

- Severe infections within 2 weeks prior to Cycle 1 Day 1

- Active or chronic viral hepatitis B or C infection

- History of or evidence of retinal pathology on ophthalmologic examination that is
considered a risk factor for central serous retinopathy, retinal vein occlusion, or
neovascular macular degeneration

- Participants will be excluded if they currently have any of the risk factors as
defined in the study protocol for retinal vein occlusion

- History of autoimmune disease

- History of idiopathic pulmonary fibrosis, organizing pneumonia, bronchiolitis
obliterans, drug-induced pneumonitis, or idiopathic pneumonitis

- History of organ transplantation including allogeneic bone marrow transplantation

- Inability to swallow medications

- Malabsorption condition that would alter the absorption of orally administered
medications

- Pregnant, lactating, breastfeeding, or intending to become pregnant during the study

- Administration of a live, attenuated vaccine within 4 weeks before randomization or
anticipation of a live attenuated vaccine will be required during the study
We found this trial at
19
sites
6401 France Avenue South
Edina, Minnesota 55435
?
mi
from
Edina, MN
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
(626) 256-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Chattanooga, Tennessee 37404
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
235 North Belle Mead Avenue
East Setauket, New York 11733
?
mi
from
East Setauket, NY
Click here to add this to my saved trials
3840 Broadway
Fort Myers, Florida 33901
?
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Harvey, Illinois 60426
?
mi
from
Harvey, IL
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
7015 A C Skinner Parkway
Jacksonville, Florida 32256
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Nashville, Tennessee 37203
?
mi
from
Nashville, TN
Click here to add this to my saved trials
333 Cedar Street
New Haven, Connecticut 06520
?
mi
from
New Haven, CT
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
5911 West Memorial Road
Oklahoma City, Oklahoma 73142
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Port Macquarie, New South Wales 2444
?
mi
from
Port Macquarie,
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Saint Petersburg, Florida 33705
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Spokane, Washington 99208
?
mi
from
Spokane, WA
Click here to add this to my saved trials
3700 O St NW
Washington, District of Columbia 20057
(202) 687-0100
Georgetown University Georgetown University is one of the world's leading academic and research institutions, offering...
?
mi
from
Washington,
Click here to add this to my saved trials
West Palm Beach, Florida 33401
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials